These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 18325493

  • 1. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
    Olsen CK, Brennum LT, Kreilgaard M.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):318-27. PubMed ID: 18325493
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response.
    Bundgaard C, Larsen F, Kreilgaard M, Brennum LT, Olsen CK.
    Biopharm Drug Dispos; 2009 May 28; 30(4):209-20. PubMed ID: 19475539
    [Abstract] [Full Text] [Related]

  • 3. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
    Seeman P, Tallerico T.
    Mol Psychiatry; 1998 Mar 28; 3(2):123-34. PubMed ID: 9577836
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
    Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J.
    Neuropsychopharmacology; 2001 Oct 28; 25(4):476-88. PubMed ID: 11557161
    [Abstract] [Full Text] [Related]

  • 5. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
    Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S.
    Schizophr Res; 2008 Oct 28; 105(1-3):224-35. PubMed ID: 18710798
    [Abstract] [Full Text] [Related]

  • 6. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat.
    Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ.
    Eur J Pharmacol; 2006 Jul 01; 540(1-3):87-90. PubMed ID: 16730699
    [Abstract] [Full Text] [Related]

  • 7. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
    Wong YC, Centanni M, de Lange ECM.
    J Clin Pharmacol; 2019 May 01; 59(5):731-747. PubMed ID: 30676661
    [Abstract] [Full Text] [Related]

  • 8. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
    Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE.
    Psychopharmacology (Berl); 1996 Mar 01; 124(1-2):57-73. PubMed ID: 8935801
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
    Matsui-Sakata A, Ohtani H, Sawada Y.
    Drug Metab Pharmacokinet; 2005 Jun 01; 20(3):187-99. PubMed ID: 15988121
    [Abstract] [Full Text] [Related]

  • 10. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.
    Am J Psychiatry; 2004 Sep 01; 161(9):1620-5. PubMed ID: 15337652
    [Abstract] [Full Text] [Related]

  • 11. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
    Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, Cumming P, Hiemke C, Rösch F, Schäfer W, Wong DF, Gründer G.
    J Clin Psychopharmacol; 2008 Dec 01; 28(6):608-17. PubMed ID: 19011428
    [Abstract] [Full Text] [Related]

  • 12. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
    Tuppurainen H, Kuikka JT, Viinamäki H, Husso M, Tiihonen J.
    Psychiatry Clin Neurosci; 2009 Aug 01; 63(4):529-37. PubMed ID: 19496999
    [Abstract] [Full Text] [Related]

  • 13. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S, Zipursky RB, Remington G.
    Am J Psychiatry; 1999 Feb 01; 156(2):286-93. PubMed ID: 9989565
    [Abstract] [Full Text] [Related]

  • 14. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS.
    Psychopharmacology (Berl); 2000 Jun 01; 150(2):132-40. PubMed ID: 10907666
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.
    JAMA Psychiatry; 2015 Sep 01; 72(9):927-34. PubMed ID: 26131622
    [Abstract] [Full Text] [Related]

  • 16. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
    Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, Sudo Y, Inoue M, Okubo Y.
    Int J Neuropsychopharmacol; 2004 Mar 01; 7(1):19-26. PubMed ID: 14764214
    [Abstract] [Full Text] [Related]

  • 17. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.
    Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F.
    Psychopharmacology (Berl); 2000 Jul 01; 150(4):422-9. PubMed ID: 10958084
    [Abstract] [Full Text] [Related]

  • 18. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
    Nakajima S, Uchida H, Bies RR, Caravaggio F, Suzuki T, Plitman E, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Mamo DC, Graff-Guerrero A.
    Schizophr Bull; 2016 Jan 01; 42(1):212-9. PubMed ID: 26221049
    [Abstract] [Full Text] [Related]

  • 19. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
    Assié MB, Dominguez H, Consul-Denjean N, Newman-Tancredi A.
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep 01; 373(6):441-50. PubMed ID: 16947046
    [Abstract] [Full Text] [Related]

  • 20. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano H, Maeda J, Okubo Y, Suhara T.
    J Clin Psychiatry; 2010 Sep 01; 71(9):1131-7. PubMed ID: 20361897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.